Aldose Reductase Inhibitors and Other Potential Therapeutic Agents for the Treatment of Diabetic Neuropathy

  • Aristidis Veves
Part of the Contemporary Endocrinology book series (COE, volume 7)


It has been more than 20 yr since the first aldose reductase inhibitor was tested in diabetic and galactosemic rats and found to control polyol accumulation (1). Since then, a considerable number of aldose reductase inhibitors have been tested in experimental and human diabetes and have considerably increased our knowledge in this field (Table 1). A thorough review of work on experimental diabetes would be outside the scope of this volume; however, the interested reader can find more information in recently published extensive reviews. The following chapter will focus on the results from clinical trials in diabetic neuropathy (2,3).


Conduction Velocity Diabetic Neuropathy Aldose Reductase Nerve Conduction Velocity Diabetic Peripheral Neuropathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Dvornik D, Simard-Duquesne N, Krami M, Sestanj K, Gabbay KH, Kinoshita JH, Varma SD, Merola LO. Polyol accumulation in galactosemic and diabetic rats: control by an aldose reductase inhibitor. Science 1973;182:1146–1148.PubMedCrossRefGoogle Scholar
  2. 2.
    Sarges R, Oates PJ. Aldose reductase inhibitors: recent developments. Prog Drug Res 1993;40:99–161.PubMedGoogle Scholar
  3. 3.
    Tomlinson DR, Willars GB, Carrington AL. Aldose reductase inhibitors and diabetic complications. Pharmacol Ther 1992;54:151–194.PubMedCrossRefGoogle Scholar
  4. 4.
    Dyck PJ, O’Brian PC. Meaningful degrees of prevention or improvement of nerve conduction in controlled clinical trials of diabetic neuropathy. Diabetes Care 1989;12:649–652.PubMedCrossRefGoogle Scholar
  5. 5.
    Culebras A, Alio J, Herrera JL, Lopez-Fraile IP. Effect of an aldose reductase inhibitor on diabetic peripheral neuropathy. Arch Neurol 1981;38:133,134.PubMedCrossRefGoogle Scholar
  6. 6.
    Handelsman DJ, Turtle JR. Clinical trial of an aldose reductase inhibitor in diabetic neuropathy. Diabetes 1981;30:459–464.PubMedCrossRefGoogle Scholar
  7. 7.
    Fagius J, Jameson S. Effects of aldose reductase inhibitor treatment in diabetic polyneuropathy a clinical and neurophysiological study. J Neurol Neurosurg Psychiatry 1981;44:991–1001.PubMedCrossRefGoogle Scholar
  8. 8.
    Judzewitsch RG, Jaspan JB, Polonsky KS, Weinberg CR, Halter JB, Halar E, Pfeifer MA, Vukadinovic C, Bernstein L, Schneider M, Liang KY, Gabbay KH, Rubenstein AH, Porte D. Aldose reductase inhibition improves nerve conduction velocity in diabetic patients. N Engl J Med 1983;308:119–125.PubMedCrossRefGoogle Scholar
  9. 9.
    Jaspan J, Maselli R, Herold K, Bartkus C. Treatment of severely painful diabetic neuropathy with an aldose reductase inhibitor: relief of pain and improved somatic and autonomic nerve function. Lancet 1983;ii:758–762.CrossRefGoogle Scholar
  10. 10.
    Young RJ, Ewing DJ, Clarke BF. A controlled trial of sorbinil, an aldose reductase inhibitor, in chronic painful diabetic neuropathy. Diabetes 1983;32:938–942.PubMedCrossRefGoogle Scholar
  11. 11.
    Lewin IG, O’Brien AD, Morgan MH, Corrall RJM. Clinical and neurophysiological studies with the aldose reductase inhibitor, sorbinil, in symptomatic diabetic neuropathy. Diabetologia 1984; 26:445–448.PubMedCrossRefGoogle Scholar
  12. 12.
    Fagius J, Brattberg A, Jameson S, Berne C. Limited benefit of treatment of diabetic neuropathy with an aldose reductase inhibitor: a 24-week controlled trial. Diabetologia 1985;28:323–329.PubMedCrossRefGoogle Scholar
  13. 13.
    O’Hare JP, Morgan MH, Alden P, Chissel S, O’Brien AD, Corrall RJM. Aldose reductase inhibition in diabetic neuropathy: clinical and neurophysiological studies of one year’s treatment with sorbinil. Diabet Med 1988;5:537–542.PubMedCrossRefGoogle Scholar
  14. 14.
    Guy RJC, Gilbey SG, Sheehy M, Asselman P, Watkins P. Diabetic neuropathy in the upper limb and the effect of twelve months sorbinil treatment. Diabetologia 1988;31:214–220.PubMedCrossRefGoogle Scholar
  15. 15.
    Consensus Statement. Report and Recommendations of the San Antonio Conference on Diabetic Neuropathy. Diabetes 1988;37:1000–1004.Google Scholar
  16. 16.
    Sima AAF, Brill V, Nathaniel T, McEwen TA, Brown MB Lattimer SA, Greene DA. Regeneration and repair of myelinated fibres in sural nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil. N Engl J Med 1988;319:548–555.PubMedCrossRefGoogle Scholar
  17. 17.
    Dyck PJ, Zimmerman BR, Vilen TH, Minnerath SR, Karnes JL, Yao JK, Poduslo JF. Nerve glucose, fructose, sorbitol, myo-inositol, and fiber degeneration and regeneration in diabetic neuropathy. N Engl J Med 1988;319:542–548.PubMedCrossRefGoogle Scholar
  18. 18.
    Gill JS, Williams G, Ghatei MA, Hetreed AH, Mather HM, Bloom SR. Effect of the aldose reductase inhibitor, ponalrestat, on diabetic neuropathy. Diabetes Metab 1990;16:296–302.Google Scholar
  19. 19.
    Price DE, Alani SM, Wales JK. Effect of aldose reductase inhibition on resistance to ischemic conduction block in diabetic subjects. Diabetes Care 1991;14:411–413.PubMedCrossRefGoogle Scholar
  20. 20.
    Ziegler D, Mayer P, Rathmann W, Gries FA. One-year treatment with the aldose reductase inhibitor, ponalrestat, in diabetic neuropathy. Diabetes Res Clin Pract 1991;14:63–73.PubMedCrossRefGoogle Scholar
  21. 21.
    Krentz AJ, Honigsberger L, Ellis SH, Hardman M, Nattrass M. A 12-month randomized controlled study of the aldose reductase inhibitor ponalrestat in patients with chronic symptomatic diabetic neuropathy. Diabet Med 1992;9:463–468.PubMedCrossRefGoogle Scholar
  22. 22.
    Boulton AJM, Levin S, Comstock J. A multicentre trial of the aldose reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy. Diabetologia 1990;33:431–437.PubMedCrossRefGoogle Scholar
  23. 23.
    Macleod AF, Boulton AJM, Owens DR, Van Rooy P, Van Gerven JMA, MacRury S, Scarpello JHB, Segers O, Heller SR, Van der Veen EA. A multicentre trial of the aldose reductase inhibitor tolrestat in patients with symptomatic diabetic peripheral neuropathy. Diabete et Metab 1992;18:14–20.Google Scholar
  24. 24.
    Santiago JV, Sonksen PH, Boulton AJM, Macleod A, Beg M, Bochenek W, Graepel GJ, Conen B. Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: Effect on nerve function. J Diab Comp 1993;7:170–178.CrossRefGoogle Scholar
  25. 25.
    Sima AAF, Greene DA, Brown MB, Hohman TC, Hicks D, Graepel GJ, Bochenek WJ, Beg M, Gonen B. Effect of hyperglycemia and the aldose inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. J Diab Comp 1993;7:157–169.CrossRefGoogle Scholar
  26. 26.
    Giugliano D, Marfella R, Quatraro A, De Rosa N, Salvatore T, Cozzolino D, Ceriello A, Torella R. Tolrestat for mild diabetic neuropathy. A 52-week, randomized, placebo controlled trial. Ann Int Med 1993;118:7–11.PubMedGoogle Scholar
  27. 27.
    Giugliano D, Acampora R, Marfella R, Di Maro G, De Rosa N, Misso L, Ceriello A, Quatraro A, D’Onofrio F. Tolrestat in the primary prevention of diabetic neuropathy. Diabetes Care 1995; 18: 536–541.PubMedCrossRefGoogle Scholar
  28. 28.
    Greene DA, Arezzo J, Brown M. Dose-related effects of the aldose reductase inhibitor zenarestat on nerve sorbitol levels, nerve conduction velocity and nerve fiber density in human diabetic neuropathy. Diabetes 1996;45(Suppl. 2):5A(abstract).Google Scholar
  29. 29.
    Greene DA, Arezzo JC, Klioze SS, Peterson MJ, Lakshminary MY. Results of phase II multicenter study of zopolrestat in patients with peripheral diabetic neuropathy. Diabetologia 1996;39(Suppl. l):A35(abstract).Google Scholar
  30. 30.
    Jamal GA. The use of gamma linolenic acid in the prevention and treatment of diabetic neuropathy. Diabetic Med 1994;11:145–149.PubMedCrossRefGoogle Scholar
  31. 31.
    Jamal GA, Carmichael H. The effect of gamma-linolenic acid on human diabetic peripheral neuropathy: a double blind placebo controlled trial. Diabetic Med 1990;7:319–323.PubMedCrossRefGoogle Scholar
  32. 32.
    Keen H, Payan J, Allawi J. Treatment of diabetic neuropathy with gamma-linolenic acid. Diabetes Care 1993;16:8–15.PubMedCrossRefGoogle Scholar
  33. 33.
    Boulton AJM, Ziegler D, Scarpello J, Jamal GA, Keen H, Aimer LO, Gamstedt A. A multicenter double-blind trial of gamolenic acid in diabetic peripheral sensorimotor neuropathy. Diabetologia 1997;40(Suppl. l):A32(abstract).Google Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Aristidis Veves

There are no affiliations available

Personalised recommendations